DATA GRAPHICS | Data Byte
How Astellas’ recent deals fit its focus areas
Japanese pharma has done a dozen therapeutics deals so far this year, with at least seven showcasing how it’s building within defined focus areas
August 8, 2023 11:36 PM UTC
Astellas has been on a deal streak this year, with its most recent agreement giving it a stake in Poseida and potentially another modality to add to its clinical pipeline. The deals brings the pharma’s therapeutic M&A, licensing and collaboration deals to 12 year-to-date.
While it’s not yet clear if or how all these deals support its stated focus areas, seven of them clearly do...